Pioneering prediction and prevention in dermatology

STOCKHOLM, SVERIGE, 28 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin disorders  announced today that it continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California.

STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces the election of Jesper Høiland as the new Chairman of the Board.

STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces that Leda Beaty has been appointed Head of US Commercial Operations.

Today, 31 May 2024, trading in the new shares and warrants of series TO 2 begins, which were issued by SciBase Holding AB (publ) ("SciBase" or the "Company") in connection with the capital raising announced by the Company on 5 April 2024, consisting of a rights issue of units of up to approximately SEK 15 million (the "Rights Issue") and a directed issue of units of approximately SEK 33 million (the "Directed Issue" and together with the Rights Issue the "Capital Raising"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023, and the Directed Issue was resolved by the Board of Directors on 5 April 2024, conditional on the subsequent approval by the general meeting. The extraordinary general meeting in the Company on 13 May 2024 resolved to approve the Board of Directors resolution to carry out the Directed Issue.

STOCKHOLM, SWEDEN, - May 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce that it has received the first order for a Nevisense system with electrodes in Austria.

STOCKHOLM, SWEDEN, - May 29, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce the launch of the eBarrier Score for Nevisense, the first-ever AI skin barrier assessment tool built for use in research and cosmetic testing. The eBarrier Score was announced today at the Cosmetotest cosmetic testing symposium in Lyon, France.

STOCKHOLM, SWEDEN, - May 22, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new clinical study has been published presenting the improvement that the Nevisense provides over visual and dermoscopic evaluation when clinical evaluations were done by German dermatologists. The article named "Utilizing Data from Electrical Impedance Spectroscopy Significantly Improves the Decision to Biopsy Pigmented Skin Lesions Beyond Clinical Evaluation and Dermoscopy" has been published in the journal "SKIN - The journal of cutaneous medicine". The study included 151 German Dermatologists making a total of 22.197 clinical biopsy decisions. Nevisense was able to improve the rate of correct biopsy choice even after dermoscopic evaluation. While dermoscopy worsened diagnostic accuracy for benign lesions, Nevisense results were able to significantly improve decision making for these lesions as well. This study demonstrates the clinical utility of Nevisense technology for improving melanoma diagnosis.

SciBase hereby announces that the Annual report for 2023 is available at the Company's website www.scibase.com.

On 5 April 2024 SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, subject to subsequent approval by the general meeting, on directed issues of a total of 77,891,769 units consisting of shares and warrants of series TO 2, with deviation from the shareholders preferential rights, to a total approximate amount of SEK 33 million (the "Directed Issue"). The subscription price in the Directed Issue amounted to SEK 0.42 per unit, corresponding to SEK 0.42 per share. The extraordinary general meeting on 13 May 2024 resolved to approve the Directed Issue. All units in the Directed Issue have been subscribed and the board of directors has therefore today, on 13 May 2024, resolved on allotment of all units in the Directed Issue.

The Board of Directors in SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome in the rights issue of so called units, consisting of shares and warrants of series TO 2 ("Units"), with preferential rights for the Company's existing shareholders of approximately SEK 15 million which was resolved upon by the Board of Directors on 5 April 2024 by virtue of the authorization from the annual general meeting on 17 May 2023 (the "Rights Issue"). The subscription price in the Rights Issue was SEK 0.42 per Unit, corresponding to SEK 0.42 per share. The warrants of series TO 2 are issued free of charge. The subscription period in the Rights Issue ended on 7 May 2024. 13,264,074 Units were subscribed for with support of unit rights, corresponding to approximately 37 percent of the Rights Issue. 8,493,194 Units, corresponding to approximately 24 percent of the Rights Issue, have been allotted to persons who have subscribed for Units without support of unit rights. In total, 21,757,268 Units were subscribed for in the Rights Issue, corresponding to approximately 61 percent of the Rights Issue. Through the Rights Issue, the Company will initially receive proceeds of approximately SEK 9 million before deduction of transaction costs. If all warrants of series TO 2 issued in the Rights Issue are exercised for subscription of shares the Company will receive additional proceeds of approximately SEK 46 million before deduction of transaction costs.

Today, 2 May 2024, is the last day of trading in unit rights in SciBase Holding AB (publ) ("SciBase" or the "Company") rights issue of units of up to approximately SEK 15 million (the "Rights Issue"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023.

STOCKHOLM, SWEDEN, - May 02, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in skin cancer detection and prevention, and prediction in dermatology, further deepens their commitment to patients and dermatologists during US Skin Cancer Awareness Month by highlighting the importance of early detection and prevention of skin cancer and helping improve outcomes for clinicians and patients.

STOCKHOLM, SWEDEN, - April 24, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Al Shirawi Healthcare solutions, a leading distributor of medical technologies across multiple specialities of aesthetics dermatology, orthopedics and medical consumables In Dubai. Through this partnership, Nevisense will now be available for patients in the United Arab Emirates (UAE).

STOCKHOLM, SWEDEN, - April 23, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders will participate at the Redeye Medtech event.

Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ("SciBase" or the "Company") rights issue of units of up to approximately SEK 15 million commences (the "Rights Issue"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023.

Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to an extraordinary general meeting to be held on 13 May 2024 at 09.00 CEST at Advokatfirman Schjødt, Hamngatan 27, in Stockholm. The registration to the meeting will open at 08.30 CEST.

The Board of Directors SciBase Holding AB (publ) ("SciBase" or the "Company") has today resolved on a capital raise totaling approximately SEK 48 million (the "Capital Raising"). The Capital Raising consists of both a new issue of so called units, consisting of shares and warrants of series TO 2, with deviation from the existing shareholders' preferential rights, of approximately SEK 33 million to Ribbskottet AB, Per Olof Ejendal AB, Kåre Gilstring, Robert Molander, MLJK Konsult AB, Klintemar Konsult AB, Jesper Hoiland, Fredrik Mattsson, Stefan Hansson, Ulti AB , Van Herk Investments B.V., Morningside Group AB, Matt Leavitt, Viktor Drvota, Theodor Invest AB and Eric Terhaerdt (the "Directed Issue"), and a new rights issue of so called units, consisting of shares and warrants of series TO 2, with preferential rights for the Company's existing shareholders of approximately SEK 15 million (the "Rights Issue"). One unit in the Rights Issue and the Directed Issue, respectively, consist of one (1) new share and five (5) warrants of series TO 2 in the Company. The Directed Issue is subject to approval by an Extraordinary General Meeting (the "EGM") intended to be held on 13 May 2024. The Company has in connection with the Rights Issue received subscription commitments totaling approximately SEK 2.5 million, corresponding to approximately 16 percent of the Rights Issue.

STOCKHOLM, SWEDEN, - February 28, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Skinobs, a leading global platform connecting researchers with the tools they need for their cosmetic and medical research. Through this partnership, SciBase will now offer Nevisense for assessing skin barrier function within cosmetic testing on the Skinobs platform.

STOCKHOLM, SWEDEN, - February 19, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders participated at the 2024 Winter Clinical Dermatology Conference in Miami. The second annual Winter Clinical Miami conference is a 4-day CME course that educates dermatologists on innovative news within Medical, and Surgical Dermatology. This prestigious CME course attracts over 400 dermatologists from the US and is considered to be one of the leading educational events for dermatology professionals.

STOCKHOLM, SWEDEN, - February 16, 2024 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the first direct comparison between electrical impedance spectroscopy (EIS) using Nevisense and trans-epidermal water loss (TEWL). The study demonstrates Nevisense as a more robust technique to assess skin barrier function than the commonly accepted TEWL measurement technique.

STOCKHOLM, SWEDEN, - January 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology initiates cooperation with Inderes (www.inderes.se) for ongoing services related to commissioned research. This collaboration aims at providing high-quality equity research on SciBase Holding AB stock.

STOCKHOLM, SWEDEN, - January 19, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day on January 25, 2024.

STOCKHOLM, SWEDEN, - January 25, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.

STOCKHOLM, SWEDEN, - December 28, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders  hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024.

STOCKHOLM, SWEDEN, - December 04, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders  announced today that it will continue its US coast-to-coast momentum with a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center ("SCARS Center") in California. This partnership will help further introduce Nevisense to a broader US market. The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks.

STOCKHOLM, SWEDEN, - November 16, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations. The Skin and Cancer Institute is a world-renowned dermatology practice group of dermatologists and skin cancer surgeons, and will be the first dermatology practice group in California to bring AI-driven technology to their patients for skin cancer detection. With more than 50 offices across a three-state network comprised of California, Arizona and Nevada, they are one of the largest dermatology groups in the country. The collaboration will provide the Skin and Cancer Institute's group with Nevisense, the only AI-driven FDA approved test for early melanoma detection at point-of-care.

The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2024:

STOCKHOLM, SWEDEN, - September 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of a collaborative scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. The study is the first to use Nevisense to measure skin barrier function in human excised skin samples, demonstrating Nevisense as an effective laboratory research device.

STOCKHOLM, SWEDEN, - September 28 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the clinical results from a study performed together with the University Children's Hospital Zürich. The study demonstrates the ability of Nevisense to distinguish children with and without Atopic Dermatitis (AD).

STOCKHOLM, SWEDEN, - September 25, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Bare Dermatology to pilot Nevisense in select locations in Texas. Bare Dermatology is a dermatology practice group in the Greater Dallas area, with five offices and a team of nationally renowned dermatologists. The agreement will provide Bare Dermatology with Nevisense, the only FDA-approved test for early melanoma detection at point-of-care.

STOCKHOLM, SWEDEN, - September 4, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby announces that Dan Walker has been appointed as VP US Commercial Operations.

STOCKHOLM, SWEDEN, - August 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that the Board has appointed Pia Renaudin as the Company's Chief Executive Officer (CEO).

Midsummer approaches and, as you know, Simon resigned a few weeks ago so we would like to give you a quick update on the recent progress at SciBase.

STOCKHOLM, SWEDEN, - May 15, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby clarifies the May 15^th announcement that Simon Grant will leave his position as CEO for personal reasons. Simon will transition out of his role over the next six months but will remain formally as CEO during this time. Simon Grant will also remain available to the Board in a consulting capacity after the end of the planned transition time.

STOCKHOLM, SWEDEN, - May 15, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that Simon Grant has resigned from his position as CEO for personal reasons and will be transitioning out of his role over the next six months. Simon Grant will remain available to the Board in a consulting capacity after the end of the planned transition time.

Headline of previously published Interim report January - March 2023 corrected including the headline in the attached pdf-file

SciBase hereby announces that the Annual report for 2022 is available at the Company's website www.scibase.com.

STOCKHOLM, SWEDEN, - April 4, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that two Medicare Administrative Contractors  (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas)   have published updated fee schedules for SciBase's early detection test for melanoma (0658T). First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. The updated fee schedules are valid retroactively from 1^st January 2023 and are available on the MAC's respective webpages.

STOCKHOLM, SWEDEN, - April 4, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that two Medicare Administrative Contractors  (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas)   have published updated fee schedules for SciBase's early detection test for melanoma (0658T). First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. The updated fee schedules are valid retroactively from 1^st January 2023 and are available on the MAC's respective webpages.

STOCKHOLM, SWEDEN, - March 29, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with Schweiger Dermatology group ("SDG") to pilot Nevisense in their Freehold, NJ office. Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut. The agreement will provide Schweiger Dermatology Group's Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.

The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the fully guaranteed rights issue of shares with preferential rights for SciBase's shareholders (the "Rights Issue") which was resolved upon by the board of directors on 13 February 2023 by virtue of the authorization from the annual general meeting on 18 May 2022. In total, 26,182,918 shares were subscribed for with support of subscription rights, corresponding to approximately 51 percent of the Rights Issue. 12,705,290 shares, corresponding to approximately 25 percent of the Rights Issue, have been allotted to persons who have subscribed for shares without support of subscription rights. Therefore, the issue guarantors are allotted approximately 24 percent of the Rights Issue. SciBase will receive approximately SEK 79.6 million before deduction for transaction costs.

The board of directors of SciBase Holding AB (publ) ("Scibase" or the "Company") has prepared a prospectus in connection with the issue of shares with preferential rights for the Company's shareholders of approximately SEK 79.6 million (the "Rights Issue") announced by the Company through press release on February 13, 2023. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company's website.

The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, by virtue of the authorization from the annual general meeting on 18 May 2022, resolved to carry out a fully guaranteed issue of new shares with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 79.6 million before transaction costs.  

STOCKHOLM, SWEDEN, - December 15, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that SciBase has received an order for skin barrier assessment products to be included  in one of the world's largest cohort studies - The ORIGINS Project, which is a collaboration between Joondalup Health Campus and Telethon Kids Institute.  SciBase will supply Nevisense, Nevisense Go and electrodes to follow up to 1,000 of the 10,000 children included in the project. Of key interest is the development and progression of atopic dermatitis and the project is intending to utilise the Nevisense system to assess skin integrity in this context.

STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to invite investors, analysts and media to a webinar on November 10 at CET 11.00 - 12.00. The event will only be digital.

STOCKHOLM, SWEDEN - November 8, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced on Monday November 7 that it has initiated a collaboration with Johnson & Johnson Consumer Health Inc. to develop  a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.

November 7, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has signed an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of a unique AI-based screening tool to predict the development of a common type of eczema called atopic dermatitis in infants.

STOCKHOLM, SWEDEN, - October 27, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a recently published article in the journal "Molecular Psychiatry", a part of Nature, named "Ectodermal origins of the skin-brain axis: a novel model for the developing brain, inflammation, and neurodevelopmental conditions"  discusses that EIS may represent an alternate clinical measure of skin barrier integrity that may function as a surrogate for neurodevelopmental divergence.

STOCKHOLM, SWEDEN, - October 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research". The study included 231 US Dermatologists making a total of 33.957 biopsy decisions. The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result. With Nevisense, Dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2% to 91.1%.

Dharminder Chahal (VanHerk Group)

Peter Elmvik (Stockholms Elbolag),

Iraj Arastoupour,

Tord Lendau (Chairman of the Board).

STOCKHOLM, SWEDEN, - September 1, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today scientific results that demonstrate the detrimental effects that common detergents can have on the health of the skin barrier. Top line results were presented recently at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. The study, which is not yet published, was performed by SIAF (CH), CK-CARE (CH), SciBase (SE) and the Sean N. Parker Allergy and Asthma research institute at Stanford (US). The study demonstrates that household laundry detergents disrupt the skin barrier integrity in mice.

STOCKHOLM, SWEDEN, - August 9, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the FDA (US Food and Drug Administration) held a meeting with the Medical Devices Advisory Committee on July 28th and 29th to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection.

2022-05-18 14:15 Today, the annual general meeting of 2022 was held in SciBase Holding AB (publ) (the “Company” or “SciBase”). Below follows a summary of the resolutions passed at the annual general meeting. The annual general meeting resolved: to adopt the profit and loss statement and the balance sheet and the group profit and loss […]

STOCKHOLM, SWEDEN, - May 16, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published in the US demonstrated that EIS and Nevisense can significantly improve clinical decisions in the dermatology day-to-day practice, especially for less experienced clinicians. The study titled - "Diagnostic Efficacy Of Electrical Impedance Spectroscopy Versus Dermoscopy For Pigmented Skin Lesions: A Pilot Study" and authored by Dr Jonathan Ungar, Associate Director and Assistant Professor, Dermatology Department, et al at Icahn School of Medicine at Mount Sinai, New York, was published online in "SKIN-The Journal of Cutaneous medicine".

January 1 - March 31, 2022

STOCKHOLM, SWEDEN, - April 29, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published this week in Germany demonstrated  the clinical benefits of Nevisense in day-to-day practice. The study titled - "Electrical Impedance Spectroscopy Improves Skin Cancer Detection and Reduces the Number of Biopsies" and authored by Dr Liebich et al was published online in the journal Dermato.

SciBase hereby announces that the Annual report for 2021 is available at the Company's website www.scibase.com.

STOCKHOLM, SWEDEN, — March 30, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that its patent application : EP Application No. 18729063.0 has been granted by EPO in Europe. This patent is linked to the new measurement procedure instituted recently with the introduction of Nevisense 3.0.
 

STOCKHOLM, SWEDEN, - March 23, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today its inclusion in the launch of a multidisciplinary research consortium focused on six different dermatological disorders. The Next Generation Immunodermatology (NGID) consortium is based in the Netherlands and will run over 6 years, leveraging the expertise from several different groups across academic, clinical, and industrial research settings. The consortium has received funding of 11.7m euros to stimulate and support innovative approaches to identify and develop novel diagnostic and therapeutic approaches within dermatology.

STOCKHOLM, SWEDEN, - March 23, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that it has received its single largest order to date from a single clinic. The order for nearly 2,000 electrodes was received from an existing customer, a private Dermatology clinic in Germany. The order was valued at around 60k€ and will be delivered in April. The company has seen a significant increase in order volume following the announcement of an 8% increase in electrode prices from April 1.

2022-02-23 08:00 January 1 – December 31, 2021 The fourth quarter in figures Net sales amounted to TSEK 3,925 (3,055). The loss after tax amounted to TSEK 13,852 (9,839). The loss per share amounted to SEK 0.20 (0.20). The cash flow from current operations was negative in the amount of TSEK 11,709 (10,290). The gross margin reached 52.8% (49.4%). […]

STOCKHOLM, SWEDEN, - January 26, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that a new study supporting the use of Nevisense in diagnosing melanoma has been published in "SKIN - The journal of cutaneous medicine". The article is authored by Avani Kolla, Prof David Polsky and others from The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine in New York. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin lesions.

SciBase has appointed Alf Laurell as Director of Quality Assurance and Regulatory Affairs and Person for Regulatory Compliance (PRRC) for SciBase. Alf joins SciBase from Elekta in Stockholm. The previous head of Quality and Regulatory and PRRC, Niklas Jakobsson has decided to pursue a new opportunity outside the company and as such leaves the SciBase Management team.

STOCKHOLM, SWEDEN, - December 22, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that a request for an appropriate Medicare payment assignment for the Nevisense procedure has been submitted to "National Government Services" (NGS), the Medicare Administrative Contractor with carrier jurisdiction responsibility for New York and several other states.

STOCKHOLM, SWEDEN, - November 29, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today, that an article describing the consequences of the new medical device regulation (MDR) in the EU has been published in the journal "Journal of the European Academy of Dermatology and Venereology" (JEADV).

Erik Esveld (VanHerk Group)

Christer Jönsson (Fouriertransform),

Iraj Arastoupour,

Tord Lendau (Chairman of the Board).

Erik Esveld (VanHerk Group)

Christer Jönsson (Fouriertransform),

Iraj Arastoupour,

Tord Lendau (Chairman of the Board).

SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CEO Simon Grant will present an update on the latest developments from SciBase at the Vator Healthcare Innovation Summit on October 7^th at 10.40 am. The presentation will be followed by a short Q&A. The Summit is a digital investor event with some of the most innovative and fast-growing Companies in healthcare represented. All presentations will be in English.

The extraordinary general meeting in SciBase Holding AB (publ) (the "Company") was held today on  September 7, 2021. Due to the extraordinary situation following the COVID-19 pandemic, the extraordinary general meeting was carried out through postal voting only, without any physical attendance. The general meeting resolved, with the required majority, as follows:

STOCKHOLM, SWEDEN, — August 19, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that the Nominating Committee proposes the election of Dr. Jvalini Dwarkasing as a new Board member at an extraordinary general meeting to be proposed by the Board of Directors of SciBase.  

SciBase Holding (publ), Reg. No. 556773-4768 (the ”Company”), hereby announces that the Company has entered into an agreement with Vator Securities AB (”Vator Securities”) regarding the service as a Certified Adviser. Vator Securities will be appointed Certified Adviser (CA) on 28 September 2021. Up until then, Avanza Bank AB will continue to act as Certified Adviser for the Company.

The extraordinary general meeting in SciBase Holding AB (publ) (the "Company") was held today on 16 June 2021. Due to the extraordinary situation following the COVID-19 pandemic, the extraordinary general meeting was carried out through postal voting only, without any physical attendance. The general meeting resolved, with the required majority, as follows:

The extraordinary general meeting in SciBase Holding AB (publ) (the "Company") was held today on 16 June 2021. Due to the extraordinary situation following the COVID-19 pandemic, the extraordinary general meeting was carried out through postal voting only, without any physical attendance. The general meeting resolved, with the required majority, as follows:

The Board of Directors of SciBase Holding AB (publ.) (“SciBase” or the “Company”) has, with support of the authorization granted by the annual general meeting on 18 May 2021 decided on a directed issue of 13,456,021 shares to a number of Swedish and international investors, including Van Herk Investments B.V. and ÖstVäst Capital Management. Furthermore, the Board of Directors has, conditioned by the approval at the extra general meeting, decided on a directed issue of 239,000 shares to the newly elected Board of Director Dr. Matt Leavitt. Notice of the extraordinary general meeting for approval of the share issue to Dr. Matt Leavitt will be announced separately.

Today, the annual general meeting of 2021 was held in SciBase Holding AB (publ) (the “Company” or “SciBase”). Below follows a summary of the resolutions passed at the annual general meeting.

STOCKHOLM, SWEDEN, — May 11, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the launch of the new Non-Melanoma Skin Cancer (NMSC) clinical application following the completion of their MDR certification process.

STOCKHOLM, SWEDEN, — May 10, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has been granted certification under the new Medical Device Regulation (MDR).

STOCKHOLM, SWEDEN, — May 4, 2021 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that an application for Medicare coverage of the Nevisense procedure has been submitted in Florida.

STOCKHOLM, SWEDEN, — May 3, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today, on "Melanoma Monday", their joint efforts with Advanced Dermatology and Cosmetic Surgery ("ADCS") - the premier dermatology network in the US with over 150 practices - to raise awareness of melanoma and educate around the dangers of the fastest growing and most deadly form of skin cancer to commemorate Skin Cancer Awareness Month.  

STOCKHOLM, SWEDEN, — April 27, 2021 – SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that the Nominating Committee proposes the election of Dr. Matt Leavitt as a new Board member to the 2021 Annual General Meeting.  

SciBase Holding AB (”SciBase” or the “Company”) has updated the Company’s financial calendar for 2021.

The shareholders in SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby given notice to attend the annual general meeting at 15:00 p.m. on Thursday 13 June 2024 at Setterwalls Advokatbyrå's offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences at 14:45 p.m. The board of directors has decided, pursuant to Chapter 7, Section 4a of the Swedish Companies Act and the Company's articles of association, to apply the possibility of postal voting in conjunction with the general meeting (see "Postal voting" below for more information).

STOCKHOLM, SWEDEN, - April 15, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a  groundbreaking article presenting the "epithelial barrier hypothesis" in Nature Reviews Immunology. The article was written by Professor Cezmi Akdis at the Swiss institute of Allergy and Asthma Research (SIAF). Prof. Akdis is the key research collaborator in SciBase's product development for skin barrier assessment. The article presents the background for the steep increase in allergic diseases over the last decades, and how this increase is connected to industrialization and modern lifestyle.

STOCKHOLM, SWEDEN, - April 12, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has today received information that the  certification process under the new Medical Device Regulation (MDR 2017/745) has been slightly delayed due to resource issues at the notified body.

STOCKHOLM, SWEDEN, - April 12, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a new clinical study supporting SciBase's strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms.

SciBase hereby announces that the Annual report for 2020 is available at the Company's website www.scibase.com.

A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases rem...

A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases rem...

• A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC) 
• The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense

• A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC) 
• The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense

• A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC) 
• The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense

Christer Jönsson (Fouriertransform), Iraj Arastoupour (Futur pension), Peter Elmvik, Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles ...

Christer Jönsson (Fouriertransform), Iraj Arastoupour (Futur pension), Peter Elmvik, Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles ...

New clinical study supports expansion of indications for Nevisense  Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer  The study publication is an important milestone in the plan...

New clinical study supports expansion of indications for Nevisense  Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer  The study publication is an important milestone in the plan...

January 1 – March 31, 2021

January 1 - September 30, 2020

Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team.    "Our manufacturing of single use electrodes is of strategic importance to the Company an...

Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team.    "Our manufacturing of single use electrodes is of strategic importance to the Company an...

STOCKHOLM, SWEDEN, - October 30, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the release of the first device based on their new platform, Nevisense Go.

STOCKHOLM, SWEDEN, - October 30, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the release of the first device based on their new platform, Nevisense Go.

STOCKHOLM, SWEDEN, - October 30, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the release of the first device based on their new platform, Nevisense Go.

SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1.

SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1.

SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

In my initial 100 days as CEO, I have been creating a roadmap for SciBase's rapid transition into a robust commercial company. I am impressed by the work that has been done so far, but I am at the same time confident that with a more focused approach, we can significantly enhance value for our shareholders, the healthcare sector, and patients.

Information about conversion of warrants (TO1) is available in the investors pages (in Swedish). Please follow the link: http://investors.scibase.se/sv/information-avseende-omvandling-av-teckningsoptioner-to1

Stockholm, Sweden and New York, USA - August 18, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that Nevi...

SciBase's head of product development, David Melin, has resigned from his position and has accepted a role at another company. The company is reviewing options for the role going forward.  "I would like to...

The nation's premier dermatology group begins rollout of Nevisense technology to examine patients with irregular moles suspicious of melanoma

Today, the annual general meeting of 2024 was held in SciBase Holding AB (publ) (the "Company" or "SciBase"). Below follows a summary of the resolutions passed at the annual general meeting, which included the election of Jesper Høiland and Robert Molander as new members of the board of directors and the election of Jesper Høiland as new chairman of the board of directors.

Stockholm, June 15th, 2020 - SciBase, a global healthcare company with a platform technology enabling innovative products for skin disorders such as skin cancer and atopic dermatitis, today announces that the company has submitted a reimbursement code application for its melanoma application to the Centers for Medicare & Medicaid Services (CMS) in the US.

Listen to the DermaLive webinar (in German), presenting “INNOVATIVE DIAGNOSTIC TOOLS IN DERMATOLOGY” (and receive CME credits). On line on June 10th at 6 PM (CET), or afterwards as a video-on-demand. Presenters are Prof Julia Welzel, Dr Martina Ulrich, Prof Uwe Reinhold and Prof Cezmi Akdis, and morderator is Prof Thomas Dirschka. Access through Streamed-up.com

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

SciBase clinical and business opportunities were presented by CEO Simon Grant at the Redeye Investor Forum Online May 12th. Please see the presentation through the following link: Redeye presentation

SciBase market potential and the opportunity to invest in the company is covered in an article by BioStock (in Swedish) See: https://www.biostock.se/2020/05/scibase-forbattrar-cancerupptackter/

I trust and hope that you are all well in these trying times. I’m very thankful that the team at SciBase has come through this unscathed so far. At the same time the landscape of our family life and our work life has undergone real changes in the recent months and I expect some of […]

The board of directors of SciBase Holding AB (publ) ("Scibase" or the "Company") has prepared a prospectus in connection with the issue of units consisting of shares and warrants with preferential rights for the Company's shareholders of up to approximately SEK 24.9 million (the "Rights Issue") announced by the Company through press release on 26 March 2020. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is available on the Company's website.

Stockholm, Sweden - SciBase (SCIB) announced today, on "Melanoma Monday", that they have entered into a collaboration agreement with Advanced Dermatology and Cosmetic Surgery ("ADCS") - the premie...

SciBase (SCIB) Stockholm, Sweden - announced today that it has received approval from the US Food and Drug Administration (FDA) for Nevisense 3.0, the third generation of their Nevisense system for early melanoma det...

SciBase AI based developments and solutions are seen as being on the forefront, and are covered in the AI Company Peltarion’s Blog: “Can a pen from the future change the lives for millions of children with eczema, asthma and allergies?” Please follow the link to read the story: https://peltarion.com/blog/applied-ai/scibase

Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved, in accordance with the proposals presented in the not...

SPECIAL PROCEDURE DUE TO THE SPREAD OF CORONAVIRUS In light of the spread of the coronavirus, the board of directors has decided to implement certain precautionary measures for the extraordinary general meeting on 29 April 2020 in order to ascertain the well-being of the company’s shareholders’ as well as the opportunity for them to exercise […]

The consequences of the Covid19 outbreak have started to affect SciBase from mid-March, and there is a high risk that these could lead to a significant financial impact on the Group. However, the effects are very difficult to predict, and the situation is constantly changing. First and foremost, we at SciBase are working to ensure […]

SciBase hereby announces that the Annual report for 2019 is available at the Company's website www.scibase.com.

SciBase Holding AB ("SciBase" or the "Company") has updated the Company's financial calendar for 2020.   Due to the preparation of the rights issue announced earlier today, the Company has r...

The shareholders of SciBase Holding AB (publ), reg. no. 556773-4768, are hereby invited to an extraordinary general meeting on Wednesday, April 29, 2020 at 10.00 a.m. CET at Setterwalls Advokatbyrå's premises at Sturegatan 10 in Stockholm, Sweden. Registration for the meeting commences 30 minutes prior to the opening of the meeting.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

SciBase, a leading manufacturer of solutions within skin diagnostics announced today that they will present at the Swiss-Nordic Bio 2020 conference in Zurich this week.   "I look forward to presenting an update...

Thomas Eklund, member of the board, has announced that he resigns effective today from the Board of SciBase Holding AB at his own request. Thomas has decided to resign from SciBase and other Board positions due to l...